Q2 FY2026 EarningsQ2 FY2026 results significantly beat consensus on the bottom line, with a net loss of $13.9M versus a $17.8M expected loss, and a GAAP EPS of -$0.14 vs. -$0.20 expected. Revenue of $5.7M surged against a zero-revenue expectation, driven by deferred revenue recognition from the Incyte partnership. Strategic workforce reductions and the pausing of the SMARCA2 program led to a 37% YoY decrease in operating expenses, extending the cash runway through Q2 2028.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Prelude Therapeutics(PRLD) the Revenue is 5.704 M (--%), Beat estimate;the EBIT is -15.45 M (+52%), Beat estimate;the EPS is -0.14 (+65.85%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B--
0.00B--
+0.01B--%
EBITExceed expectations
-0.02B52.00%
-0.02B41.30%
+0.00B10.70%
EPSExceed expectations
-0.1465.85%
-0.196752.03%
+0.056713.82%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf